Inovio Pharmaceuticals - 48 Year Dividend History | INO

Historical dividend payout and yield for Inovio Pharmaceuticals (INO) since 1971. The current TTM dividend payout for Inovio Pharmaceuticals (INO) as of June 18, 2019 is $0.00. The current dividend yield for Inovio Pharmaceuticals as of June 18, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.253B $0.030B
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.806B 12.30
Gilead Sciences (GILD) United States $85.546B 10.39
Bio-Techne Corp (TECH) United States $7.848B 53.55